Phase 4 Completed N=30 Randomized Treatment

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

Blepharitis

Source: ClinicalTrials.gov NCT01478256 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2013

Primary outcomePrimary: Improvement in Signs and Symptoms of Blepharitis — 15; 15 participants

Summary

This study looks at the improvements in signs and symptoms in patients with inflammation of the lids, blepharitis, using two different FDA approved topical antibiotic agents, Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients for microbiologic evidence of improvement.

Outcome Measures

Outcome	Result	p-value
PRIMARY Improvement in Signs and Symptoms of Blepharitis	15; 15	—
SECONDARY Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics	15; 15	—

Eligibility Criteria

Inclusion Criteria:Acute blepharitis, age 18-100, Signs and symptoms of blepharitis - Exclusion Criteria: women of child bearing potential, eye surgery within three months of study, contact lens wear, use of topical or antibacterial agents in past two weeks, use of topical or oral steroids in past two weeks unless stable dosage -

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01478256). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.